Concord Biotech Limited — PPTs, 30-05-2025: Investor Presentation

1. Financial Highlights:

Concord Biotech reported Q4 revenue of ₹429.9 Cr, up 35% YoY, and FY25 revenue of ₹1,200.1 Cr, up 18% YoY. EBITDA grew 42% in Q4 to ₹190.4 Cr (44.3% margin), with FY25 EBITDA at ₹506.3 Cr, up 17% (42.2% margin). PAT rose 48% in Q4 to ₹140.4 Cr (32.7% margin) and 21% for FY25 to ₹371.6 Cr (31% margin). Gross margin slightly contracted by ~200 bps but stayed healthy at 70%. API sales form 81%-83% of revenue; formulations grew 38% for FY25 contributing 22%. Total assets increased to ₹2,034 Cr, equity at ₹1,813 Cr driven by capacity expansions and investments.

2. Strategic Initiatives & Growth Drivers:

Commissioned a new injectable manufacturing facility at Valthera (Unit IV), boosting specialty injectable capacity. USFDA ANDA approval for Teriflunomide Tablets taps into a $402Mn US and $908Mn global market. Investments in Palvella Therapeutics and CleanMax support rare disease therapy expansion and adoption of renewable energy at the Dholka plant. Strong R&D with 10+ products in pipeline across oncology, anti-infectives, and antifungals.

3. Business Developments:

Advanced global filings with new DMFs and ANDA approvals, expanding regulated market presence. Exploring CDMO/CMO opportunities leveraging fermentation expertise and scale. Successfully cleared multiple regulatory inspections including USFDA and EU GMP. Strategic investments enhance specialty pharma reach and sustainability credentials.

4. Market Position & Competitive Advantage:

Leader in fermentation-based APIs with 30+ niche products in immunosuppressants, oncology, and anti-infectives. Backward integration, large fermentation capacity (1,250 m3), and strong regulatory compliance create high entry barriers. Integrated API and formulation platform spans 70+ countries and 250+ customers, diversifying revenue and increasing wallet share.

5. Investor Implications:

Double-digit revenue and profit growth supported by capacity additions and regulatory nods indicate positive growth potential. New injectable facility and USFDA approvals enable deeper penetration into high-value segments. Investments in CDMO, rare diseases, and sustainability add long-term upside. Execution risk exists in scaling injectables and product launches, but strong R&D and compliance mitigate concerns. Concord presents a compelling growth and innovation story in fermentation-based biopharma.